Renascience, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Mojo Score Change: Renascience, Inc. has changed its score on 05 Dec 2025. Click here to unlock latest mojo score!

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Operating profit has grown by an annual rate 4.82% of over the last 5 years

With ROE of -10.23%, it has a attractive valuation with a 13.77 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

JPY 25,411 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-12.46%

Price to Book

15.37

Revenue and Profits:

Net Sales:

10 Million

(Quarterly Results - Jun 2025)

Net Profit:

-67 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-10.18%

6 Months

-18.55%

1 Year

480.54%

2 Years

303.26%

3 Years

414.88%

4 Years

120.1%

5 Years

0.0%

Renascience, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Renascience, Inc. Hits Day Low at JPY 2,001 Amid Price Pressure

Renascience, Inc., a small-cap pharmaceutical company, faced a notable stock decline today, reaching an intraday low. Despite a strong year-to-date performance, recent financial metrics reveal challenges, including negative return on equity and significant drops in operating profit and net sales, indicating potential inefficiencies and rising costs.

Renascience, Inc. Hits Day High with 12.97% Surge Amid Market Decline

Renascience, Inc., a small-cap biotechnology firm, saw a notable stock price increase on October 14, 2025, amidst a declining market. Over the past week, it has outperformed the Japan Nikkei 225 index significantly, with impressive year-to-date gains, despite facing financial challenges and a negative return on equity.

Renascience, Inc. Hits Day High with 15.79% Surge in Stock Price

Renascience, Inc. has seen a notable rise in its stock price, achieving significant gains over the past week and year. However, the company faces challenges, including negative return on equity and a substantial decline in net sales, creating a complex financial situation despite its impressive stock performance.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.61%

EBIT Growth (5y)

4.82%

EBIT to Interest (avg)

-238.51

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.05

Sales to Capital Employed (avg)

0.08

Tax Ratio

21.10%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

13.77

EV to EBIT

-122.43

EV to EBITDA

-122.48

EV to Capital Employed

-274.84

EV to Sales

165.00

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-10.23%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -75.00% vs -57.22% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -295.86% vs -868.18% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10.00",
          "val2": "40.00",
          "chgp": "-75.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-102.30",
          "val2": "-36.50",
          "chgp": "-180.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "20.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-66.90",
          "val2": "-16.90",
          "chgp": "-295.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-10,227.40%",
          "val2": "-911.50%",
          "chgp": "-931.59%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is -31.67% vs 93.23% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 143.90% vs 23.08% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "132.70",
          "val2": "194.20",
          "chgp": "-31.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-178.80",
          "val2": "-250.40",
          "chgp": "28.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "322.80",
          "val2": "-4.50",
          "chgp": "7,273.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "113.40",
          "val2": "-258.30",
          "chgp": "143.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,347.70%",
          "val2": "-1,299.60%",
          "chgp": "-4.81%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

10.00

40.00

-75.00%

Operating Profit (PBDIT) excl Other Income

-102.30

-36.50

-180.27%

Interest

0.00

Exceptional Items

0.00

20.00

-100.00%

Consolidate Net Profit

-66.90

-16.90

-295.86%

Operating Profit Margin (Excl OI)

-10,227.40%

-911.50%

-931.59%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is -75.00% vs -57.22% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -295.86% vs -868.18% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

132.70

194.20

-31.67%

Operating Profit (PBDIT) excl Other Income

-178.80

-250.40

28.59%

Interest

0.00

Exceptional Items

322.80

-4.50

7,273.33%

Consolidate Net Profit

113.40

-258.30

143.90%

Operating Profit Margin (Excl OI)

-1,347.70%

-1,299.60%

-4.81%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is -31.67% vs 93.23% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 143.90% vs 23.08% in Mar 2024

All Annual Results

Company CV

About Renascience, Inc.

Renascience, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Renascience, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor Management Efficiency with a low ROE of 0%

Poor long term growth as Operating profit has grown by an annual rate 4.82% of over the last 5 years

With ROE of -10.23%, it has a attractive valuation with a 13.77 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Renascience, Inc. Hits Day Low at JPY 2,001 Amid Price Pressure

Renascience, Inc. Hits Day High with 12.97% Surge Amid Market Decline

Renascience, Inc. Hits Day High with 15.79% Surge in Stock Price

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Mar'25

About Renascience, Inc.

Company Coordinates